A bit of light shed in these paragraphs on the timings of the next stages of development for the BARD-1 kits, which had been queried a few times on the HC threads. Looks like the BARD-1 ovarian kit validation at Griffith will only actually begin next month, with results due Q1 CY21:
"The Company is now moving forward with an independent BARD1-Ovarian cancer validation study at Griffith University to test the robustness of the algorithm in new samples of ovarian cancer and healthy controls. The study is expected to commence in November 2020 and be completed in the first quarter of the 2021 calendar year, once the new samples are received from the Victorian Cancer Biobank."
"The Company is also on-track with plans to further optimise and validate the BARD1-Breast cancer test on the Luminex platform, commencing in the first half of the 2021 calendar year."
Ann: Appendix 4C and Quarterly Activities Report, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
0.015(2.65%) |
Mkt cap ! $63.96M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 58.0¢ | 56.0¢ | $38.51K | 68.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2293 | 56.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 13111 | 1 |
View Market Depth
| Last trade - 15.48pm 12/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |